Article Figures & Data
Tables
Doses Low (25-100 mg daily) Medium (300-600 mg daily) High (> 800 mg daily) Receptors Histamine 1 Alpha 1/alpha 2 adrenergic 5-HT1A, 5-HT2A/B, 5-HT2C D2 Activity Antihistaminergic Antiadrenergic Serotonergic Antidopaminergic Effect Sedation Antidepressant properties Antipsychotic properties At baseline Body mass index Waist circumference Blood pressure Fasting glucose Fasting lipids After initiation Electrocardiography Potassium level Extrapyramidal side effects (using the Abnormal Involuntary Movement Scale [AIMS]) At 4, 8, and 12 weeks after initiation Body mass index Three months after initiation Blood pressure Fasting glucose Fasting lipids Routinely at follow-up visits Body mass index Extrapyramidal side effects (using AIMS) Signs of misuse, abuse, or other drug-seeking behavior Annually Blood pressure Fasting glucose Fasting lipids With dose or risk factor changes Electrocardiography Potassium level Based on information in reference 20.
In this issue
Jump to section
- Article
- ABSTRACT
- AN INCREASINGLY POPULAR DRUG
- POTENTIAL FOR ABUSE
- DIFFERENT DOSES HAVE DIFFERENT EFFECTS
- PHARMACOKINETIC PROFILE LENDS ITSELF TO ABUSE
- ADVERSE EFFECTS
- CONCERNS FOR THE ELDERLY
- STANDARD INSOMNIA MEDICATIONS HAVE DISADVANTAGES
- IS QUETIAPINE THE ANSWER?
- MANY BELIEVE OFF-LABEL QUETIAPINE TO BE SAFER THAN ALTERNATIVES
- CLINICAL RECOMMENDATIONS
- BOTTOM LINE
- DISCLOSURES
- REFERENCES
- Figures & Data
- Info & Metrics